BICC1 Fusion

CI-VAR-00001204Explore in graph →CIViC 782

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Cholangiocarcinoma3
FGFR2::BICC1 Fusion	(diagnostic)	Diagnostic	B	Supports Positive	4	accepted	EID1846 Massively parallel whole transcriptome sequencing in eight specimens from cholangiocarcinoma patients identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1. In RT-PCR screening, the FGFR2 f… (full text at CIViC) PMID 24122810 · Arai et al., 2014 · Open in CIViC	civic
FGFR2::BICC1 Fusion	Futibatinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID11629 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Intrahepatic Cholangiocarcinoma1
FGFR2::BICC1 Fusion	Futibatinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11610 In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC	civic

Malignant Endometrial Neoplasm1
FGFR2::BICC1 Fusion	Erdafitinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1920 Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 … (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC	civic

Transitional Cell Carcinoma1
FGFR2::BICC1 Fusion	Erdafitinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID1917 Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without known FGFR pathway aberrations. Among 23 patients with FGFR pathway aberratio… (full text at CIViC) PMID 26324363 · Tabernero et al., 2015 · Open in CIViC	civic